
|Articles|June 21, 2021
- June 2021
- Volume 27
- Issue 4
Weidner et al, Appendices
Appendices to: Observations Regarding the Average Sales Price Reimbursement Methodology
Advertisement
Articles in this issue
over 4 years ago
Dollars and Senseover 4 years ago
Real-World Evidence Is Key to Accelerating Oncology Approvalsover 4 years ago
Biosimilars Drive Savings in Medicare’s Oncology Care Modelover 4 years ago
A Social Worker Leads ACCC, and Her Timing Is PerfectNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
2
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS
3
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
4
The Changing Treatment Landscape of IPF and PPF: Toby Maher, MD, PhD
5














































